Insomnia Treatment Guidelines

Introduction to Insomnia Management

The American Academy of Sleep Medicine's 2008 clinical guideline for chronic insomnia explicitly lists recommended benzodiazepines for insomnia, but notably excludes alprazolam from this list 1

The American Academy of Sleep Medicine recommends non-benzodiazepine BzRAs, such as zolpidem 10 mg, eszopiclone 2-3 mg, and zaleplon 10 mg, as first-line pharmacotherapy for insomnia 1, 2, 3
Melatonin receptor agonist ramelteon 8 mg is particularly suitable for patients with substance use history, with no DEA scheduling and no dependence potential 2, 3
If traditional benzodiazepines are necessary, use only those with established efficacy for insomnia, such as temazepam 15-30 mg, triazolam 0.25 mg, and estazolam 1-2 mg 1

Hypnotic medications should be prescribed for the shortest duration possible, ideally 2-4 weeks maximum, to minimize tolerance and dependence 1
CBT-I should be offered as first-line treatment before or alongside any pharmacotherapy, as it provides sustained improvement without tolerance, dependence, or withdrawal issues 2, 3
Never combine any benzodiazepine or BzRA with alcohol or other CNS depressants, and exercise extreme caution in patients taking opioids due to additive respiratory depression risk 1, 4
Elderly patients require dose reductions of all hypnotics due to increased fall risk and cognitive impairment, and patients with respiratory compromise require careful consideration, with non-benzodiazepine BzRAs preferred over traditional benzodiazepines 1, 3